Menopur

Menotropin, the active ingredient in Menopur, is a gonadotropin (FSH/LH) preparation presented as a powder for solution for injection for subcutaneous use. It treats infertility caused by anovulation and supports assisted reproductive technology procedures in women.

GNH USA supplies Menopur as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, fertility clinics and pharmacies worldwide with strict quality, regulatory compliance and reliable cold‑chain logistics.

Menopur is used in reproductive medicine to stimulate ovarian follicular development in specific infertility contexts.

Anovulatory infertility: promotes follicular growth to enable ovulation. IVF cycles: enhances ovarian response to stimulation, increasing the number of retrieved oocytes. Ovarian stimulation for egg retrieval: improves the yield of mature oocytes for assisted reproduction. Donor egg programs: facilitates controlled ovarian hyperstimulation to obtain donor oocytes. Endometriosis‑related infertility: may be incorporated into stimulation protocols to improve oocyte yield.

Menopur may cause a range of adverse reactions, which are generally related to its hormonal activity and injection route.

Common Side Effects: - Injection site pain or erythema - Mild ovarian hyperstimulation syndrome (abdominal discomfort, bloating) - Nausea or vomiting - Headache - Fatigue

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome (rapid weight gain, shortness of breath) - Thromboembolic events (deep vein thrombosis, pulmonary embolism) - Anaphylactic or severe allergic reactions - Ovarian torsion

When using Menopur, clinicians should observe several precautionary measures to minimize risks and ensure optimal outcomes.

Baseline ovarian assessment: evaluate follicular reserve before initiating therapy. Monitor for ovarian hyperstimulation syndrome: watch for abdominal distension, rapid weight gain, or shortness of breath. Avoid use in uncontrolled thyroid disease: correct thyroid function prior to treatment. Use cautiously in hormone‑sensitive tumors: assess risk‑benefit ratio. Pregnancy testing: confirm negative pregnancy before starting. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menopur can interact with other medications that affect hormonal balance or coagulation, requiring careful management.

Major Interactions (Avoid): - GnRH agonists: concurrent use may increase risk of severe ovarian hyperstimulation. - Estrogen‑containing contraceptives: antagonize Menopur’s stimulatory effect on the ovary.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for thromboembolic events if ovarian hyperstimulation occurs. - Corticosteroids: may alter ovarian response, adjust monitoring. - Insulin sensitizers (e.g., metformin): observe glucose control during stimulation.